Ranibizumab Biosimilar - Research Grade

Product Specifications

Background

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A) . Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.

Product Name Alternative

Vascular endothelial growth factor

UniProt

P15692

Host

Humanized

Reactivity

Human

Target

VEGF

Isotype

IgG1 κ

Sequence

https://www.imgt.org/mAb-DB/

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

References & Citations

Giannos, S.A., Kraft, E.R., Luisi, J.D. et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharm Res 41, 1247–1256 (2024) .

Shipping Conditions

Blue ice

Storage Conditions

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.